Industry News

CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced the launch of Olerup QTYPE ® at the 42 nd Annual Meeting of the American Society of Histocompatability and Immunogenetics in St. During a lunchtime symposium on the pre-to-post transplant continuum, John Lunz, PhD, from the Gift of Hope Organ..."/>
CareDx Launches Olerup QTYPE® at ASHI  
Cigna by Anthem would hurt competition in the individual health insurance market on Obamacare's exchanges. The antitrust regulators sued in July to stop the deal and another in which Hartford-based Aetna would purchase Humana, arguing that limited health care competition would increase costs for consumers, doctors and hospitals."/>
Justice Department Modifies Anthem-Cigna Lawsuit [The Hartford Courant]
Cotiviti Holdings, Inc., a leading payment accuracy provider to the healthcare and retail industries, announced today the successful completion of the previously announced refinancing of its first and second lien term loans and revolving credit facility. Cotiviti Corporation and certain other subsidiaries of the company entered into a Restated Credit Agreement comprised of a $250 million term loan A due in September 2021; a $550 million term loan B due in September..."/>
Cotiviti Holdings, Inc. Announces Completion of Refinancing
Precision Optics Corporation, Inc. today announced operating results on an unaudited basis for its fourth quarter and fiscal year ended June 30, 2016.. Revenues of $963 thousand in the fourth quarters of fiscal 2016 and 2015; 87% year-over-year increase in quarterly engineering service revenue; 51% year-over-year increase in quarterly gross profit, with gross margin of 33.2% compared to 21.9%; Continued progress toward conversion of engineering..."/>
Precision Optics Corporation, Inc. Announces Operating Results for the Fourth Quarter and Fiscal Year Ended June 30, 2016
Charles River Laboratories International, Inc. announced today that it has acquired Agilux Laboratories, Inc., a Worcester, Massachusetts-based contract research organization, that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. The company’ s unique..."/>
Charles River Laboratories Acquires Agilux Laboratories, Inc.
Veeva Systems today announced details for the 2016 Veeva Global R&D Summit. The third annual event will be held from October 17-19, 2016 at the Loews Philadelphia Hotel and features speakers from the world’ s leading pharmaceutical companies and biotechs, including Abbvie, Eli Lilly and Company, and Merck."/>
Veeva R&D Summit to Feature Six of the Top 25 Largest Pharmaceutical Companies and Leading Biotechs
Epicore BioNetworks Inc. is pleased to announce that a new director has joined the board, effective September 6, 2016. Donald R. Siemens of Langley, B.C., Canada. Siemens holds a bachelor's degree from the University of British Colombia and has over 40 years' experience as a chartered accountant."/>
Epicore BioNetworks Inc. Announces Corporate Actions
Amgen today announced positive top-line results for erenumab from A Phase 3, R andom I zed, double-blind, placebo-controlled S tudy to E valuate the efficacy and safety of erenumab in migraine prevention. These data showed the ARISE study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients with episodic migraine treated with erenumab compared with..."/>
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
Epicore BioNetworks Inc. is pleased to announce that a new director has joined the board, effective September 6, 2016. The Board welcomes Mr. Donald R. Siemens of Langley, B.C., Canada. Siemens holds a bachelor's degree from the University of British Colombia and has over 40 years' experience as a chartered accountant."/>
Epicore BioNetworks Inc. Announces Corporate Actions
WellCare Health Plans, Inc. today announced that it will release its financial results for the third quarter 2016 on Tuesday, November 1, 2016, at approximately 6:30 a.m. EDT. The company will also host a conference call at 8:30 a.m. EDT that morning to discuss its financial results. The conference call will be webcast live from the company's website and will be available at the following link:..."/>
WellCare to Release Third Quarter 2016 Results on November 1, 2016
Landauer, Inc., a recognized leader in personal and environmental radiation measurement and monitoring and outsourced medical physics services, today announced that Teri G. Fontenot has been appointed to the Board of Directors, effective September 28, 2016, expanding the Company's Board to nine directors. Fontenot has nearly 35 years of experience in leading healthcare organizations. She is currently the President and Chief..."/>
Landauer, Inc. Appoints Teri Fontenot to Board of Directors
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the closing of an underwritten offering of 2,875,000 shares of its common stock, including 375,000 shares purchased by the underwriter pursuant to the exercise in full of its option to purchase additional shares, at a price of $4.00 per share. Catabasis received gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and other..."/>
Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated a Phase 1 clinical study and has begun dosing healthy adults with EDP-305, Enanta’ s lead farnesoid X..."/>
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Merrimack Pharmaceuticals, Inc. today announced it will present six posters from its systems-biology derived antibody engineering and nanotherapeutic portfolios at the European Society for Medical Oncology 2016 Congress, October 7– 11, 2016 in Copenhagen, Denmark. Merrimack will present the final results of the Phase 3 NAPOLI-1 study in a poster discussion session and a NAPOLI-1 safety-over-time subset analysis in a separate..."/>
Merrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan’ s Ministry of Health, Labor& Welfare has approved JUXTAPID for patients with homozygous familial hypercholesterolemia.. HoFH is a serious, rare genetic disease that impairs the function of the receptor responsible for removing LDL-C..."/>
Aegerion Pharmaceuticals’ JUXTAPID® (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the distribution of TREXIMET ® 10/ 60 mg to wholesalers has begun. TREXIMET 10/ 60 mg is indicated for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. ¹ TREXIMET received U.S. Food and Drug Administration approval for use in the pediatric population 12 years of age..."/>
Pernix Therapeutics Announces Distribution of TREXIMET® 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients
Intra-Cellular Therapies, Inc. today announced top-line results from the second Phase 3 clinical trial of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale total score, in the pre-defined patient population. The active control, risperidone, did separate from..."/>
Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study ‘302)
Genmab A/S. Copenhagen, Denmark; September 28, 2016- Genmab A/S announces under reference to Section 29 of the Danish Securities Trading Act that Baillie Gifford& Co has corrected their previous notification of September 22, 2016."/>
Major Shareholder Announcement
Tactile Systems Technology of northeast Minneapolis has been a winner for shareholders since it went public in July at a price of $10 per share. The fast-growing medical products company, which does business as Tactile Medical, raised more than $40 million in its offering. The stock closed Friday at $20.18 per share, a nearly doubling of shareholder value to more than $320 million."/>
IPO market remains a shadow of its former self [Star Tribune (Minneapolis)]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology648 Articles
Consumer Discretionary550 Articles
Financials387 Articles
Industrials366 Articles
Health Care337 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at